BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38712849)

  • 1. Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post-onset ΔFS for study design and medical practice.
    Ludolph AC; Corcia P; Desnuelle C; Heiman-Patterson T; Mora JS; Mansfield CD; Couratier P
    Muscle Nerve; 2024 Jul; 70(1):36-41. PubMed ID: 38712849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Revised amyotrophic lateral sclerosis functional rating scale at time of diagnosis predicts survival time in amyotrophic lateral sclerosis].
    Liu XX; Fan DS; Zhang J; Zhang S; Zheng JY
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(35):2472-5. PubMed ID: 20137433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the diagnosis delay and ALS functional impairment at diagnosis as relevant criteria for clinical trial enrolment.
    Hamidou B; Marin B; Lautrette G; Nicol M; Camu W; Corcia P; Arnes-Bes MC; Tranchant C; Clavelou P; Hannequin D; Maurice G; Beauvais K; Antoine JC; Danel-Brunaud V; Viader F; Preux PM; Couratier P
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Nov; 18(7-8):519-527. PubMed ID: 28762856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and neurophysiological biomarkers of disease progression in amyotrophic lateral sclerosis.
    Hannaford A; Byth K; Pavey N; Henderson RD; Mathers S; Needham M; Schultz D; Menon P; Kiernan MC; Vucic S
    Muscle Nerve; 2023 Jan; 67(1):17-24. PubMed ID: 36214183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of disease progression rate and related factors in amyotrophic lateral sclerosis patients at initial visit].
    Zhang JH; Wang HF; Yang F; He ZQ; Feng F; Li M; Bai JM; Wang HR; Huang XS
    Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(3):222-227. PubMed ID: 35042292
    [No Abstract]   [Full Text] [Related]  

  • 6. The prognostic value of spirometric tests in Amyotrophic Lateral Sclerosis patients.
    Pirola A; De Mattia E; Lizio A; Sannicolò G; Carraro E; Rao F; Sansone V; Lunetta C
    Clin Neurol Neurosurg; 2019 Sep; 184():105456. PubMed ID: 31382080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal comparison of the self-entry Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-RSE) and Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis.
    Johnson SA; Burke KM; Scheier ZA; Keegan MA; Clark AP; Chan J; Fournier CN; Berry JD
    Muscle Nerve; 2022 Oct; 66(4):495-502. PubMed ID: 35904151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy.
    Mandrioli J; Biguzzi S; Guidi C; Sette E; Terlizzi E; Ravasio A; Casmiro M; Salvi F; Liguori R; Rizzi R; Pietrini V; Borghi A; Rinaldi R; Fini N; Chierici E; Santangelo M; Granieri E; Mussuto V; De Pasqua S; Georgoulopoulou E; Fasano A; ; Ferro S; D'Alessandro R
    Neurol Sci; 2015 Dec; 36(12):2243-52. PubMed ID: 26205535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurophysiological indices in amyotrophic lateral sclerosis correlate with functional outcome measures, staging and disease progression.
    Barp A; Lizio A; Gerardi F; Tarlarini C; Mauro L; Sansone VA; Lunetta C
    Clin Neurophysiol; 2021 Jul; 132(7):1564-1571. PubMed ID: 34023632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study.
    Kjældgaard AL; Pilely K; Olsen KS; Jessen AH; Lauritsen AØ; Pedersen SW; Svenstrup K; Karlsborg M; Thagesen H; Blaabjerg M; Theódórsdóttir Á; Elmo EG; Møller AT; Bonefeld L; Berg M; Garred P; Møller K
    BMC Neurol; 2021 Apr; 21(1):164. PubMed ID: 33865343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rate of disease progression: a prognostic biomarker in ALS.
    Labra J; Menon P; Byth K; Morrison S; Vucic S
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):628-32. PubMed ID: 26152368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials.
    Daghlas I; Lever TE; Leary E
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):206-211. PubMed ID: 29260911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
    Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
    JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.
    Genge A; Cedarbaum JM; Shefner J; Chio A; Al-Chalabi A; Van Damme P; McDermott C; Glass J; Berry J; van Eijk RPA; Fournier C; Grosskreutz J; Andrews J; Bertone V; Bunte TM; Couillard M; Cummings C; Kittle G; Polzer J; Salmon K; Straub C; van den Berg LH
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 May; 25(3-4):382-387. PubMed ID: 38396337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS.
    Kimura F; Fujimura C; Ishida S; Nakajima H; Furutama D; Uehara H; Shinoda K; Sugino M; Hanafusa T
    Neurology; 2006 Jan; 66(2):265-7. PubMed ID: 16434671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change.
    Young CA; Chaouch A; Mcdermott CJ; Al-Chalabi A; Chhetri SK; Talbot K; Malaspina A; Mills R; Tennant A
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 May; 25(3-4):400-409. PubMed ID: 38426231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between nutritional status and disease severity using the amyotrophic lateral sclerosis (ALS) functional rating scale in ALS patients.
    Park Y; Park J; Kim Y; Baek H; Kim SH
    Nutrition; 2015; 31(11-12):1362-7. PubMed ID: 26429656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late-onset patients with sporadic amyotrophic lateral sclerosis in Japan have a higher progression rate of ALSFRS-R at the time of diagnosis.
    Tanaka Y; Yoshikura N; Harada N; Yamada M; Koumura A; Sakurai T; Hayashi Y; Kimura A; Hozumi I; Inuzuka T
    Intern Med; 2012; 51(6):579-84. PubMed ID: 22449665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study.
    Hu N; Shen D; Yang X; Cui L; Liu M
    Acta Neurol Belg; 2022 Dec; 122(6):1567-1573. PubMed ID: 35034333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.